managing t790-negative egfr-mutated nsclc
Published 7 years ago • 338 plays • Length 13:06Download video MP4
Download video MP3
Similar videos
-
19:28
managing t790-positive egfr-mutated nsclc
-
20:27
managing egfr-resistant disease: t790 and beyond
-
21:35
long term management of egfr-mutant nsclc -tsao
-
24:36
treatment options for egfr t790m negative acquired resistance
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
20:35
tki-resistant egfr-mutant nsclc
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
1:04:03
hfpef series treatments
-
21:23
immunotherapy for targeted therapies - what do we know helena yu, md
-
28:17
segment 1: egfr tkis in nsclc
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
7:12
egfr mutated adenocarcinoma - case based panel discussions
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
3:24
options for egfr mutation-positive patients with t790m mutation-negative acquired resistance
-
5:59
targeted therapy in consolidation setting for lung cancer
-
41:19
targeting egfr to enhance nkt cell-mediated killing of lung cancer cells